Author:
Tan Fenlai,Shen Xiaoyan,Wang Dechang,Xie Guojian,Zhang Xiaodong,Ding Lieming,Hu Yunyan,He Wei,Wang Yanping,Wang Yinxiang
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference27 articles.
1. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Hematol,1995
2. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry;Liu;J Chromatogr B,2009
3. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial;Zhao,2009
4. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors;Zhao;Lung Cancer,2011
5. A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China;Zhao,2010
Cited by
124 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献